|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-6-20
|
|
pubmed:abstractText |
Methotrexate (MTX) is used as a second-line immuno-modulator in patients with inflammatory bowel disease when purine analogs are not tolerated or lack efficacy. High-level evidence indicates efficacy for intramuscular administration in Crohn's disease, but there are few reports of experience with subcutaneous delivery. This study aimed to evaluate the response to and tolerance of MTX where subcutaneous administration was the preferred option.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1440-1746
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
954-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17559377-Adult,
pubmed-meshheading:17559377-Aged,
pubmed-meshheading:17559377-Aged, 80 and over,
pubmed-meshheading:17559377-Colitis, Ulcerative,
pubmed-meshheading:17559377-Crohn Disease,
pubmed-meshheading:17559377-Female,
pubmed-meshheading:17559377-Humans,
pubmed-meshheading:17559377-Immunosuppressive Agents,
pubmed-meshheading:17559377-Injections, Subcutaneous,
pubmed-meshheading:17559377-Male,
pubmed-meshheading:17559377-Medical Records,
pubmed-meshheading:17559377-Methotrexate,
pubmed-meshheading:17559377-Middle Aged,
pubmed-meshheading:17559377-Retrospective Studies,
pubmed-meshheading:17559377-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
|
|
pubmed:affiliation |
Department of Gastroenterology and Monash University Department of Medicine, Box Hill Hospital, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article
|
